Monoclonal Antibody Therapeutics Market by Source, End User, Application - Global Forecast 2025-2030- Product Image

Sale

Monoclonal Antibody Therapeutics Market by Source, End User, Application - Global Forecast 2025-2030

Report
196 Pages
October 2024
Region: Global
360iResearch™
ID: 4829819

UP TO €695EUR$697USD£573GBP OFF until Dec 31^st 2024

The Monoclonal Antibody Therapeutics Market grew from USD 153.35 billion in 2023 to USD 169.87 billion in 2024. It is expected to continue growing at a CAGR of 11.34%, reaching USD 325.37 billion by 2030.

Monoclonal antibody therapeutics are highly targeted treatments designed using clones of a single parent cell, offering specificity in addressing a wide range of diseases such as cancer, autoimmune disorders, and infectious diseases. These therapeutics are crucial for providing precision medicine, offering the ability to bind specifically to disease-causing antigens, thus minimizing side effects and enhancing efficacy. They have found application across various healthcare settings, with oncology, immunology, and infectious diseases being the primary end-use areas. Increasing prevalence of chronic diseases, advancements in genetic research, and rising demand for personalized medicine drive the market growth. Furthermore, substantial investments in biotechnology research and a growing number of approvals from regulatory bodies like the FDA present potential opportunities for innovation and expansion in this field. Notably, emerging markets in Asia-Pacific are poised for robust growth due to increased healthcare expenditure and improved access to healthcare facilities. However, the market faces challenges such as high development costs, complex manufacturing processes, and stringent regulatory requirements that can impede growth. In addition, the ethical concerns and potential for immunogenic reactions present limitations in the broader adoption of these therapeutics. Companies should explore biosimilars production as an area of innovation, which offers cost-effective alternatives and can break the monopolization of market leaders. Additionally, research into novel antibody formats, like bispecific antibodies, could offer enhanced therapeutic effects. Strategic collaborations for technology development, along with leveraging artificial intelligence to optimize antibody design and production, can further drive market competitiveness. The monoclonal antibody therapeutics market is characterized by rapid advancements and competition, with an ongoing shift towards diversification of therapeutic applications and streamlined production processes, offering significant potential for business growth and continuous innovation.

Understanding Market Dynamics in the Monoclonal Antibody Therapeutics Market

The Monoclonal Antibody Therapeutics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Growing incidences of chronic and genetic diseases across the world and the need for urgent treatment strategies
- Favorable regulatory approvals for monoclonal antibodies
- Government initiatives to promote access to critical monoclonal antibody therapies for patients
Market Restraints
- Production issues and difficulties associated with storage and handling
Market Opportunities
- Ongoing advancements and R&D activities to improve the efficacy and safety of monoclonal antibody therapeutics
- Inclinations towards personalized medicine and incorporation of antibody-drug conjugates for treatment
Market Challenges
- Performance limitations and variability in treatment effect

Exploring Porter’s Five Forces for the Monoclonal Antibody Therapeutics Market

Porter’s Five Forces framework further strengthens the insights of the Monoclonal Antibody Therapeutics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Monoclonal Antibody Therapeutics Market

External macro-environmental factors deeply influence the performance of the Monoclonal Antibody Therapeutics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Monoclonal Antibody Therapeutics Market

The Monoclonal Antibody Therapeutics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Monoclonal Antibody Therapeutics Market

The Monoclonal Antibody Therapeutics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Monoclonal Antibody Therapeutics Market

The Monoclonal Antibody Therapeutics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Monoclonal Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Envigo, F. Hoffmann-La Roche Ltd, GenScript, GlaxoSmithKline Plc, Johnson & Johnson, Merck Sharp & Dohme Corp.,, Novartis International AG, Pfizer Inc, and Sanofi S.A.

Market Segmentation & Coverage

This research report categorizes the Monoclonal Antibody Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Source
- Chimeric
- Human
- Humanized
End User
- Hospitals
- Private Clinics
- Research Institute
Application
- Autoimmune Diseases
- Cancer
- Hematological Diseases
- Infectious Diseases
- Ophthalmological Diseases

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidences of chronic and genetic diseases across the world and the need for urgent treatment strategies
5.1.1.2. Favorable regulatory approvals for monoclonal antibodies
5.1.1.3. Government initiatives to promote access to critical monoclonal antibody therapies for patients
5.1.2. Restraints
5.1.2.1. Production issues and difficulties associated with storage and handling
5.1.3. Opportunities
5.1.3.1. Ongoing advancements and R&D activities to improve the efficacy and safety of monoclonal antibody therapeutics
5.1.3.2. Inclinations towards personalized medicine and incorporation of antibody-drug conjugates for treatment
5.1.4. Challenges
5.1.4.1. Performance limitations and variability in treatment effect
5.2. Market Segmentation Analysis
5.2.1. Source: Rising prevalence of human monoclonal antibodies due to their lower immunogenicity
5.2.2. End User: Increasing adoption in hospitals necessity for precise diagnostic oversight and administration typically involving intravenous infusion
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Monoclonal Antibody Therapeutics Market, by Source

6.1. Introduction
6.2. Chimeric
6.3. Human
6.4. Humanized

7. Monoclonal Antibody Therapeutics Market, by End User

7.1. Introduction
7.2. Hospitals
7.3. Private Clinics
7.4. Research Institute

8. Monoclonal Antibody Therapeutics Market, by Application

8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cancer
8.4. Hematological Diseases
8.5. Infectious Diseases
8.6. Ophthalmological Diseases

9. Americas Monoclonal Antibody Therapeutics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Monoclonal Antibody Therapeutics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Monoclonal Antibody Therapeutics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Roche Pharma India Enters into Ophthalmology with Dual-Pathway-Inhibitor Vabysmo
12.3.2. Partnership between AbbVie and OSE Immunotherapeutics for Chronic Inflammation Treatment
12.3.3. Novartis Expands Autoimmune Portfolio with Acquisition of Calypso Biotech
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio

List of Figures

FIGURE 1. MONOCLONAL ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. MONOCLONAL ANTIBODY THERAPEUTICS MARKET DYNAMICS
FIGURE 7. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 10. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. MONOCLONAL ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 37. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 38. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 39. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 40. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 43. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 44. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 45. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 46. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 47. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 48. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 49. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 50. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 51. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 52. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 53. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 54. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 55. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 56. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 57. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 58. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 59. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 60. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 61. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 62. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 63. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 64. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 65. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 66. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 67. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 68. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 69. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 70. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 71. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 72. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 73. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 74. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 76. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 78. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 80. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 82. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 83. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 84. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 85. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 86. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 87. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 88. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 89. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 90. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 91. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 92. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 93. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 94. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 95. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 96. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 97. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 98. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 99. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 100. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 101. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 102. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 103. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 104. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 105. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 106. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 107. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 108. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 109. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 110. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 111. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 112. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 113. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 114. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 115. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 116. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 117. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 118. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 119. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 120. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 121. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 122. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 123. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 124. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 125. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 126. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 127. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 128. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 129. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 130. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 131. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 132. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 133. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 134. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 135. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 136. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 137. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 138. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 139. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 140. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 141. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 142. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 143. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 144. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 145. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 146. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 147. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 148. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 149. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 150. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 151. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 152. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 153. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 154. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 163. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 164. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 165. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 166. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 167. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 168. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 169. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 170. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 171. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 172. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 173. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 174. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 175. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 176. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 177. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 178. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 179. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 180. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 181. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 182. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 183. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 184. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 185. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 186. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 187. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 188. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 189. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 190. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 191. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 192. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 193. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 194. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 195. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 196. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 197. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 198. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 199. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 200. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 201. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 202. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 203. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 204. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 205. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 206. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 207. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 208. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 209. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 210. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 211. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 212. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 213. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 214. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 215. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 216. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 217. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 218. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 219. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 220. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 221. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 222. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 223. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 224. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 225. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 226. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 227. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 228. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 229. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 230. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 231. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 232. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 233. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 234. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 235. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 236. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 237. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 238. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 239. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 240. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 242. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 244. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 246. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 248. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 250. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 252. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 253. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 254. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 255. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 256. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 257. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 258. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 259. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 260. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 261. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 262. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 263. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 264. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 265. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 266. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 267. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 268. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 269. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 270. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 271. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 272. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 273. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 274. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 275. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 276. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
TABLE 284. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 286. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 288. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 289. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 290. MONOCLONAL ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Monoclonal Antibody Therapeutics market, which are profiled in this report, include:

AbbVie Inc.
Amgen Inc.
Bayer AG
Biogen Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Envigo
F. Hoffmann-La Roche Ltd
GenScript
GlaxoSmithKline Plc
Johnson & Johnson
Merck Sharp & Dohme Corp.,
Novartis International AG
Pfizer Inc
Sanofi S.A

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	196
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 169.87 Billion
Forecasted Market Value ( USD ) by 2030	$ 325.37 Billion
Compound Annual Growth Rate	11.3%
Regions Covered	Global
No. of Companies Mentioned	15

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3535EUR$3,545USD£2,916GBP €3928EUR$3,939USD£3,239GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6255EUR$6,272USD£5,158GBP €6950EUR$6,969USD£5,731GBP

Understanding Market Dynamics in the Monoclonal Antibody Therapeutics Market

Exploring Porter’s Five Forces for the Monoclonal Antibody Therapeutics Market

Applying PESTLE Analysis to the Monoclonal Antibody Therapeutics Market

Analyzing Market Share in the Monoclonal Antibody Therapeutics Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Monoclonal Antibody Therapeutics Market

Strategic Recommendations for Success in the Monoclonal Antibody Therapeutics Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Biosimilar Monoclonal Antibodies Market by Drug Class, Application - Global Forecast 2025-2030

Monoclonal Antibodies Market by Source Type, Production Type, Indication, End-User - Global Forecast 2025-2030

Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Forecast to 2029

Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030

Monoclonal Antibodies (MAs) Global Market Report 2024